Target Price | $33.66 |
Price | $21.45 |
Potential |
56.92%
register free of charge
|
Number of Estimates | 10 |
10 Analysts have issued a price target Catalyst Pharmaceuticals, Inc. 2026 .
The average Catalyst Pharmaceuticals, Inc. target price is $33.66.
This is
56.92%
register free of charge
$42.00
95.80%
register free of charge
$31.31
45.97%
register free of charge
|
|
A rating was issued by 14 analysts: 13 Analysts recommend Catalyst Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Catalyst Pharmaceuticals, Inc. stock has an average upside potential 2026 of
56.92%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 491.73 | 572.23 |
23.49% | 16.37% | |
EBITDA Margin | 47.28% | 39.09% |
57.71% | 17.33% | |
Net Margin | 33.33% | 31.74% |
85.85% | 4.77% |
10 Analysts have issued a sales forecast Catalyst Pharmaceuticals, Inc. 2025 . The average Catalyst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Catalyst Pharmaceuticals, Inc. EBITDA forecast 2025. The average Catalyst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Catalyst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Catalyst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 1.31 | 1.49 |
107.94% | 13.74% | |
P/E | 14.40 | |
EV/Sales | 3.56 |
10 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast for earnings per share. The average Catalyst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Catalyst Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
Baird |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Jan 09 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
Analyst Rating | Date |
---|---|
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
Locked
Baird:
Locked
➜
Locked
|
Feb 04 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 09 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.